Advanced

Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis

Svensson, B and Pettersson, Holger LU (2003) In Scandinavian Journal of Rheumatology 32(2). p.83-88
Abstract
Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression... (More)
Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression in patients treated with CPH82 was similar to that in patients treated with MTX. The clinical effect of the two drugs was sustained over the two year trial in both treatment groups. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
randomized trial, Larsen score, progression, x-ray, early rheumatoid arthritis, methotrexate, Reumacon, CPH82
in
Scandinavian Journal of Rheumatology
volume
32
issue
2
pages
83 - 88
publisher
Taylor & Francis
external identifiers
  • wos:000182235800004
  • pmid:12737326
  • scopus:0037258334
ISSN
1502-7732
DOI
language
English
LU publication?
yes
id
c7bdfed1-c991-4768-bc1e-10d1afafe343 (old id 313234)
date added to LUP
2007-09-23 09:12:24
date last changed
2018-05-29 09:53:33
@article{c7bdfed1-c991-4768-bc1e-10d1afafe343,
  abstract     = {Objectives. To study x-ray development and clinical effects, tolerability and safety after 2 years treatment of RA patients with Reumacon (CPH82) or methotrexate (MTX). Patients and methods. This study is a 74 week open continuation of a 24 week double blind comparison of 100 patients with early RA (disease duration less than 2 years) treated either with Reumacon or MTX. Results. The mean Larsen scores and the mean number of erosions increased significantly from baseline to 24 weeks and from 24 weeks to endpoint in both groups with no significant difference between them. Both groups had improved significantly in all clinical variables after 24 weeks and this improvement was sustained after two years. Conclusions. Radiological progression in patients treated with CPH82 was similar to that in patients treated with MTX. The clinical effect of the two drugs was sustained over the two year trial in both treatment groups.},
  author       = {Svensson, B and Pettersson, Holger},
  issn         = {1502-7732},
  keyword      = {randomized trial,Larsen score,progression,x-ray,early rheumatoid arthritis,methotrexate,Reumacon,CPH82},
  language     = {eng},
  number       = {2},
  pages        = {83--88},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Rheumatology},
  title        = {Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis},
  url          = {http://dx.doi.org/},
  volume       = {32},
  year         = {2003},
}